<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777411</url>
  </required_header>
  <id_info>
    <org_study_id>EV-RB1401</org_study_id>
    <nct_id>NCT02777411</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old</brief_title>
  <official_title>An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enimmune Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enimmune Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the immune response and safety profiles of two
      injections of EV71 vaccine administrated with or without adjuvant AlPO4 at 0.5-μg, 1-μg, 2-μg
      and 5-μg dose (if required) in children aged 3 to 6 years old and 0.25-μg (if required),
      0.5-μg, 1-μg and 2-μg (if required) in 6 to 35 months old infants/toddlers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>7 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>28 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of overall adverse events (AEs) and serious adverse event (SAEs)</measure>
    <time_frame>Day 0 to Day 196</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunoglobulin G (IgG) titers induced by the EV71 vaccine ( determined by ELISA)</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum neutralizing antibody titers (NT) induced by the EV71 vaccine</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate (SCR) based on neutralizing antibody titers</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the laboratory results based on hematology tests in each visit</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the laboratory results based on biochemistry tests in each visit</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in heart rates at each visit (for the 3 to 6 years old group only)</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood pressures at each visit (for the 3 to 6 years old group only)</measure>
    <time_frame>Day 28, Day 56, Day 196</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Enterovirus Infections</condition>
  <arm_group>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 to 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 to 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 to 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 to 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to 35 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to 35 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to 35 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group A3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine (2 μg total protein per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group A4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine (1 μg total protein per dose)</intervention_name>
    <description>Two vaccinations at 28 days apart</description>
    <arm_group_label>Group B4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy children aged from 3 to 6 years old (i.e. ≥ 3 years old and &lt; 7 years old) for
             Part A; from 6 to 35 months old (i.e. ≥ 6 months old and &lt; 36 months old) for Part B
             at the time of first vaccination.

          2. Subject's guardians were able and willing to comply with study procedures and give
             written informed consent.

          3. Subject was able and could comply with the requirements of the protocol.

          4. Subject with body temperature ≤38°C.

        Exclusion Criteria:

          1. Subject with previous known exposure to Enterovirus 71 (EV71).

          2. Subject with a history of herpangina, hand-foot-mouth disease, acute hemorrhagic
             conjunctivitis associated with enterovirus infection in the past 3 months.

          3. Subject with gestation &lt; 37 weeks.

          4. Subject with birth weight &lt;2.5 kg.

          5. Subject with a history of hypersensitivity to vaccines, or a history of allergic
             disease or reactions likely to be exacerbated by any component of the vaccine.

          6. Family history of seizures or progressive neurological disease.

          7. Family history of congenital or hereditary immunodeficiency.

          8. Severe malnutrition or dysgenopathy.

          9. Major congenital defects or serious chronic illness, including perinatal brain damage.

         10. Subject diagnosed of having autoimmune disease (e.g., celiac disease, type I diabetes,
             lupus (SLE), juvenile dermatomyositis, scleroderma, juvenile idiopathic arthritis
             (JIA), immune (or idiopathic) thrombocytopenia purpura).

         11. Bleeding disorder diagnosed by a doctor or significant bruising or bleeding
             difficulties with IM injections or blood draws.

         12. Any acute infections 7 days prior to administrate the first vaccination.

         13. Use of any investigational product (including drug, vaccine) within 30 days prior to
             vaccination or planned use during the study period.

         14. Administration of any attenuated live vaccine within 7 days prior to vaccination.

         15. Use of immunoglobulins or any blood products within 3 months prior to vaccination or
             planned use during the study period.

         16. Chronic administration (defined as &gt; 14 days) of immunosuppressants or other
             immunomodulators or systemic corticosteroids within 6 months prior to vaccination.

         17. Under anti-tuberculosis prevention or therapy.

         18. Any condition that in the opinion of the investigator may interfere with the
             evaluation of study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Tao Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines</keyword>
  <keyword>Hand, Foot and Mouth Disease</keyword>
  <keyword>EV71 enteroviruses vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

